^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    AWT020

    i
    Other names: AWT020, Mableukin​-2PD1
    Associations

    News

    Trials
    Company:
    Anwita Biosci
    Drug class:
    PD1 inhibitor, IL-2 stimulant
    Related drugs:
    Associations

    News

    Trials
    3ms
    Phase 1 Study of AWT020 in Advanced Cancer (clinicaltrials.gov)
    P1, N=30, Recruiting, Anwita Biosciences | Phase classification: P1/2 --> P1
    Phase classification • Metastases
    |
    AWT020
    6ms
    Phase 1 Study of AWT020 in Advanced Cancer (clinicaltrials.gov)
    P1/2, N=30, Recruiting, Anwita Biosciences
    New P1/2 trial • Metastases
    |
    AWT020
    over1year
    A safe and highly potent PD-1-IL-2 fusion (AWT020) that decouples the efficacy and toxicity of IL-2 therapy (SITC 2022)
    Ethics Approval The protocol of animal studies has been reviewed and approved by IACUC. Download figure Open in new tab Download powerpoint Abstract 1104 Figure 1 MOA of AWT020AWT020 is highly specific to tumor infiltrated T cells
    Clinical • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • IL2RA (Interleukin 2 receptor, alpha) • CD3D (CD3d Molecule) • CXCR3 (C-X-C Motif Chemokine Receptor 3) • CXCR6 (C-X-C Motif Chemokine Receptor 6) • STAT5A (Signal Transducer And Activator Of Transcription 5A)
    |
    AWT020